CAR T-cell Therapy
EBV-specific CTLs for Neuroblastoma
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new way to fight neuroblastoma, a form of cancer, by combining two different types of cells that each attack the disease in different ways. The new cell is made by attaching an antibody that recognizes neuroblastoma cells to a type of cell that normally fights infectious mononucleosis. This new cell is given to patients with neuroblastoma that has returned and is not responding to other treatments.
Virus Therapy
HLA-matched VSTs for Viral Infections Post Stem Cell Transplant
Recruiting1 awardPhase 1
Houston, Texas
This trial is for patients who have had a stem cell transplant and have developed a viral infection that is not responding to standard therapy. In this trial, the patient will receive white blood cells that have been specially trained to fight the viral infection.
CAR T-cell Therapy
Adoptive Immunotherapy for Viral Infections
Recruiting1 awardPhase 1 & 2
Washington, District of Columbia
This trial is a Phase I-II dose-finding trial to determine the optimal dose of intravenous injection of donor-derived cytotoxic T lymphocytes specific for CMV, EBV, BKV, and Adenovirus.
CAR T-cell Therapy
Genetically Modified T cells for Leukemia and Lymphoma
Recruiting1 awardPhase 1
New York, New York
This trial is testing the safety of giving patients modified T-cells from a donor. The goal is to see if these cells cause any toxicities in patients with relapsed B cell leukemia or lymphoma.
Popular Filters
Trials for Diffuse Large B-Cell Lymphoma Patients
CAR T-cell Therapy
T-cell Therapy for Lymphoma
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new way to fight cancer by combining two existing methods. Antibodies stick to cancer cells, and T cells are special infection-fighting blood cells that can kill other cells. The hope is that by combining these two methods, the cancer cells will be killed more effectively.
CAR T-cell Therapy
EBV-Specific Cytotoxic T-Lymphocytes for Lymphoma
Recruiting1 awardPhase 1
Houston, Texas
This trial is for people with Hodgkin or non-Hodgkin lymphoma, T/NK-lymphoproliferative disease, or severe chronic active Epstein Barr Virus (CAEBV) that has come back or is at risk of coming back.
Trials for Marginal Zone Lymphoma Patients
CAR T-cell Therapy
T-cell Therapy for Lymphoma
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new way to fight cancer by combining two existing methods. Antibodies stick to cancer cells, and T cells are special infection-fighting blood cells that can kill other cells. The hope is that by combining these two methods, the cancer cells will be killed more effectively.
CAR T-cell Therapy
EBV-Specific Cytotoxic T-Lymphocytes for Lymphoma
Recruiting1 awardPhase 1
Houston, Texas
This trial is for people with Hodgkin or non-Hodgkin lymphoma, T/NK-lymphoproliferative disease, or severe chronic active Epstein Barr Virus (CAEBV) that has come back or is at risk of coming back.
Trials for EBV Positive Patients
Monoclonal Antibodies
Rituximab + LMP-Specific T-Cells for Post-transplant Lymphoproliferative Disease
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is testing if a combination of rituximab and LMP-specific T-cells is more effective than rituximab alone in treating pediatric patients with post-transplant lymphoproliferative disorder.
CAR T-cell Therapy
EBV-Specific Cytotoxic T-Lymphocytes for Lymphoma
Recruiting1 awardPhase 1
Houston, Texas
This trial is for people with Hodgkin or non-Hodgkin lymphoma, T/NK-lymphoproliferative disease, or severe chronic active Epstein Barr Virus (CAEBV) that has come back or is at risk of coming back.
CAR T-cell Therapy
EBV-Specific T-Cell Therapy for Lymphoma
Recruiting1 awardPhase 1
Houston, Texas
This trial is for patients with Hodgkin or non-Hodgkin lymphoma that has come back or has not gone away after treatment, who also show signs of Epstein Barr virus. T cells will be infused that have been genetically modified to target and kill cancer cells infected with EBV. The goal is to find the largest safe dose and evaluate how long the cells can be detected in the blood and what affect they have on cancer.
Virus Therapy
Tabelecleucel for EBV Associated Diseases
Recruiting1 awardPhase 2
Orange, California
This trial tests tabelecleucel, a treatment using special immune cells, in patients with certain diseases related to the Epstein-Barr virus (EBV) who can't use or don't respond to standard treatments. It works by enhancing the immune system's ability to attack virus-infected cells. Tabelecleucel is being tested for recurring or hard-to-treat EBV-related diseases.
Trials With No Placebo
Monoclonal Antibodies
STAR0602 for Advanced Cancers
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing a new drug called STAR0602 to see if it is safe and effective for treating advanced cancers with specific markers. The drug is given through an IV and aims to find and destroy cancer cells by recognizing these markers. The study will first determine the best dose and then see how well the drug works in patients.
CAR T-cell Therapy
R-MVST Cells for Viral Infections
Recruiting1 awardPhase 1
New York, New York
This trial is testing a cell therapy called R-MVST for safety and feasibility in patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. The cell therapy will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available.
Mitotic Inhibitor
Chemotherapy and Radiation Based on EBV DNA for Nasopharyngeal Cancer
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial tests different combinations of chemotherapy drugs and radiation therapy for advanced nasopharyngeal cancer. It targets patients whose cancer has not spread beyond the local region. The treatment works by killing cancer cells or stopping their growth using powerful drugs and radiation. Previous studies have shown a survival benefit using a combination of these treatments for nasopharyngeal carcinoma.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.